In sum, we propose that the current work describes a defective cell cycle pathway with cancer-like properties involved in AVM development and identifies anti-cancer CDK4/6 inhibitors as potential therapeutics for HHT. This evidence concerns the gene CDK4 and hereditary hemorrhagic telangiectasia.